Abstract:In-silico identification of potential target genes for disease is an essential aspect of drug target discovery. Recent studies suggest that successful targets can be found through by leveraging genetic, genomic and protein interaction information. Here, we systematically tested the ability of 12 varied algorithms, based on network propagation, to identify genes that have been targeted by any drug, on gene-disease data from 22 common non-cancerous diseases in OpenTargets. We considered two biological networks, six performance metrics and compared two types of input gene-disease association scores. The impact of the design factors in performance was quantified through additive explanatory models. Standard cross-validation led to over-optimistic performance estimates due to the presence of protein complexes. In order to obtain realistic estimates, we introduced two novel protein complex-aware cross-validation schemes. When seeding biological networks with known drug targets, machine learning and diffusion-based methods found around 2-4 true targets within the top 20 suggestions. Seeding the networks with genes associated to disease by genetics decreased performance below 1 true hit on average. The use of a larger network, although noisier, improved overall performance. We conclude that diffusion-based prioritisers and machine learning applied to diffusion-based features are suited for drug discovery in practice and improve over simpler neighbour-voting methods. We also demonstrate the large impact of choosing an adequate validation strategy and the definition of seed disease genes.The use of biological network data has proven its effectiveness in many areas from computational biology. Networks consist of nodes, usually genes or proteins, and edges that connect pairs of nodes, representing information such as physical interactions, regulatory roles or co-occurrence. In order to find new candidate nodes for a given biological property, the so-called network propagation algorithms start from the set of known nodes with that property and leverage the connections from the biological network to make predictions. Here, we assess the performance of several network propagation algorithms to find sensible gene targets for 22 common non-cancerous diseases, i.e. those that have been found promising enough to start the clinical trials with any compound. We focus on obtaining performance metrics that reflect a practical scenario in drug development where only a small set of genes can be essayed. We found that the presence of protein complexes biased the performance estimates, leading to over-optimistic conclusions, and introduced two novel strategies to address it. Our results support that network propagation is still a viable approach to find drug targets, but that special care needs to be put on the validation strategy. Algorithms benefitted from the use of a larger -although noisier- network and of direct evidence data, rather than indirect genetic associations to disease.

Learning the Drug Target-Likeness of A Protein

Does Drug-Target Have A Likeness?

Identification of Human Protein Drug Targets Homologues with Data Mining

Prediction of Potential Drug Targets Based on Simple Sequence Properties

Analysis of protein features and machine learning algorithms for prediction of druggable proteins

Machine learning prediction of oncology drug targets based on protein and network properties

A probabilistic knowledge graph for target identification

The Application of in Silico Drug-Likeness Predictions in Pharmaceutical Research.

Are Topological Properties of Drug Targets Based on Protein-Protein Interaction Network Ready to Predict Potential Drug Targets?

Therapeutic targets: Progress of their exploration and investigation of their characteristics (vol 58, pg 259, 2006)

Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning

Exploration of Target Spaces in the Human Genome for Protein and Peptide Drugs

Support vector machines approach for predicting druggable proteins: recent progress in its exploration and investigation of its usefulness.

Machine learning for target discovery in drug development

DrugProtAI: A guide to the future research of investigational target proteins

Drug—target network

Prediction of Drug Targets for Specific Diseases Leveraging Gene Perturbation Data: A Machine Learning Approach

Progress and Problems in the Exploration of Therapeutic Targets.

Using Compound Similarity and Functional Domain Composition for Prediction of Drug-Target Interaction Networks.

Benchmarking network propagation methods for disease gene identification

Prediction of drug-target interactions for drug repositioning only based on genomic expression similarity